Lilly And Novo Nordisk Shape Up For Obesity Treatment Battle Of The Heavyweights
Over The Counter 10 July 2023: Prescription Slimming Drugs And Their OTC Alternatives, With OptiBiotix’s Stephen O’Hara
Listen to this article
In this episode, we explore recent consumer interest in prescription weight loss drugs such as Novo Nordisk's Wegovy with gut health expert Stephen O’Hara. As CEO of microbiome specialist OptiBiotix Health, O’Hara points to over-the-counter alternatives like prebiotic food supplements and medical devices, which may offer similar hunger-reducing benefits without the side effects associated with these drugs. By successfully negotiating health claim regulations, as well as investing in new markets and in new delivery formats like gummies, companies like Optibiotix are looking to take advantage of this new interest in slimming solutions, he explains.
Explore how consumer health is evolving. On the go.
More from Europe
In a major milestone for the EU’s pricing and reimbursement landscape, the European Commission has published the first ever, much anticipated, joint clinical assessment report.
• By
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
• By
Weak demand for virus-blocking nasal sprays since the pandemic has left Austrian biotech Marinomed with mounting debts. The company has applied for restructuring proceedings with an Austrian court in an attempt to secure its future.
• By
Perrigo aims its new SolpaOne high-strength paracetamol effervescent at UK pharmacists, who now have expanded powers as part of the UK government's Pharmacy First initiative.
More from Geography
• By
Court order dismisses claims against Perrigo and Joseph Papa, its former CEO, with prejudice. Settlement also bars any claim against plaintiffs and class members, “whether arising under state, federal, common or foreign law,” alleging liability for losses.
• By
In this episode of the Over the Counter podcast, HBW Insight speaks to Kerry's RDA senior manager of immune and joint health, Sonja Nodland, about the opportunity for innovation that postbiotics represent for the consumer health industry.
• By
Proposal to have panelists rate the strength of efficacy and safety evidence on a numeric scale also draws support in written comments on ways to optimize the advisory committee process.